David Malcom Rodman Sells 25,482 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 25,482 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $15.03, for a total value of $382,994.46. Following the sale, the insider now owns 135,974 shares in the company, valued at approximately $2,043,689.22. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Mineralys Therapeutics Stock Down 0.8 %

NASDAQ:MLYS traded down $0.12 during trading hours on Friday, hitting $14.04. 329,448 shares of the company's stock traded hands, compared to its average volume of 146,487. Mineralys Therapeutics, Inc. has a 52 week low of $5.85 and a 52 week high of $16.91. The firm has a market cap of $698.21 million, a P/E ratio of -5.18 and a beta of 1.71. The business's fifty day simple moving average is $12.90 and its two-hundred day simple moving average is $12.61.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.10). During the same period in the previous year, the firm posted ($0.31) earnings per share. On average, analysts expect that Mineralys Therapeutics, Inc. will post -3.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research note on Thursday, October 31st.

Institutional Investors Weigh In On Mineralys Therapeutics

A number of institutional investors have recently made changes to their positions in MLYS. SG Americas Securities LLC purchased a new stake in Mineralys Therapeutics during the 3rd quarter valued at about $110,000. Bellevue Group AG bought a new position in shares of Mineralys Therapeutics in the first quarter worth approximately $119,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Mineralys Therapeutics by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company's stock worth $116,000 after buying an additional 3,732 shares during the period. Federated Hermes Inc. raised its holdings in Mineralys Therapeutics by 100.0% during the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company's stock valued at $140,000 after buying an additional 6,000 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in Mineralys Therapeutics during the 2nd quarter valued at $145,000. Hedge funds and other institutional investors own 84.46% of the company's stock.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.